DFX Intelligence

Data Factory

BVF Inc/il

Office on the family office graph

This is the graph view. The full profile, with its team, deals and sources, is on Family Offices.Open the full profile →

Search this name across graphsid dfx:fo:047506d3-9b4e-4640-8a43-9523b53109c7

Data as of an unrecorded date (this record's last observation) from Sworn filings; Announcements. Page built Sep 18, 2026, 10:56 PM UTC and rebuilt at most every 15 minutes.

Relationships: 130
Dated events: 40
On other graphs: 0
Observed: n/a to n/a

Across DFX

This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.

People

Person	Title	Role	Seniority	Family member	Current	Evidence
Mark N. Lampert	President	leadership	senior	n/a	yes	fact

Relationships

showing 80 of 130

Invested in (65)

→ Allakos Inc.CompanyInsider stake
May 19, 2025 to presentfactSEC filings
→ POINT Biopharma Global Inc.CompanyInsider stake
Dec 20, 2023 to presentfactSEC filings
→ Structure Therapeutics Inc.CompanyInsider stake
Feb 13, 2023 to presentfactSEC filings
→ ESSA Pharma Inc.CompanyInsider stake
Jul 21, 2022 to presentfactSEC filings
→ 4D Molecular Therapeutics, Inc.CompanyInsider stake
Jun 27, 2022 to presentfactSEC filings
→ Verastem, Inc.CompanyInsider stake
Feb 7, 2022 to presentfactSEC filings
→ Cullinan Oncology, Inc.CompanyInsider stake
Jan 10, 2022 to presentfactSEC filings
→ Repare Therapeutics Inc.CompanyInsider stake
Nov 8, 2021 to presentfactSEC filings
→ Olema Pharmaceuticals, Inc.CompanyInsider stake
May 26, 2021 to presentfactSEC filings
→ Rain Therapeutics Inc.CompanyInsider stake
May 17, 2021 to presentfactSEC filings
→ CytomX Therapeutics, Inc.CompanyInsider stake
Dec 28, 2020 to presentfactSEC filings
→ Eledon Pharmaceuticals, Inc.CompanyInsider stake
Oct 5, 2020 to presentfactSEC filings
→ Kymera Therapeutics, Inc.CompanyInsider stake
Aug 25, 2020 to presentfactSEC filings
→ Principia Biopharma Inc.CompanyInsider stake
Aug 20, 2020 to presentfactSEC filings
→ IDEAYA Biosciences, Inc.CompanyInsider stake
Jun 22, 2020 to presentfactSEC filings
→ CYTOKINETICS INCCompanyInsider stake
Dec 12, 2019 to presentfactSEC filings
→ Calithera Biosciences, Inc.CompanyInsider stake
Oct 31, 2019 to presentfactSEC filings
→ FIVE PRIME THERAPEUTICS, INC.CompanyInsider stake
Oct 2, 2019 to presentfactSEC filings
→ GLYCOMIMETICS INCCompanyInsider stake
Aug 26, 2019 to presentfactSEC filings
→ XOMA CorpCompanyInsider stake
Nov 29, 2018 to presentfactSEC filings
→ PIERIS PHARMACEUTICALS, INC.CompanyInsider stake
Nov 26, 2018 to presentfactSEC filings
→ Syndax Pharmaceuticals IncCompanyInsider stake
Dec 8, 2017 to presentfactSEC filings
→ Regulus Therapeutics Inc.CompanyInsider stake
Nov 27, 2017 to presentfactSEC filings
→ CONCERT PHARMACEUTICALS, INC.CompanyInsider stake
Oct 23, 2017 to presentfactSEC filings
→ Nivalis Therapeutics, Inc.CompanyInsider stake
May 11, 2017 to presentfactSEC filings
→ INFINITY PHARMACEUTICALS, INC.CompanyInsider stake
Dec 20, 2016 to presentfactSEC filings
→ Xenon Pharmaceuticals Inc.CompanyInsider stake
Sep 12, 2016 to presentfactSEC filings
→ CTI BIOPHARMA CORPCompanyInsider stake
Dec 14, 2015 to presentfactSEC filings
→ Regado Biosciences IncCompanyInsider stake
Feb 10, 2014 to presentfactSEC filings
→ Oncothyreon Inc.CompanyInsider stake
Aug 2, 2013 to presentfactSEC filings
and 35 more

Related to (15)

→ Venture Capital Portfolio 2020 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Tactical Opportunities Portfolio Te 2022 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Tactical Opportunites Portfolio 2020 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Venture Capital Portfolio Te 2024 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Secondaries Portfolio Te 2023 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Real Estate Portfolio Te 2024 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Real Estate Portfolio Te 2023 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Real Estate Portfolio Te 2022 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Real Estate Portfolio Te 2021 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Real Estate Portfolio 2020 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Real Assets Portfolio Te 2024 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Real Assets Portfolio Te 2023 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Real Assets Portfolio Te 2022 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Real Assets Portfolio Te 2021 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF
→ Secondaries Portfolio Te 2024 LPFunda foundation at the office's address (ADDITIONAL VENTURES FOUNDATION) holds it
inferenceForm 990-PF

Dated events

40 bookkeeping events (roster, classification and holdings changes) folded below

Show 40 bookkeeping events

First seen by DFX
Sep 13, 2026
date not stated
BVF Inc/il: PROBABLE_SFO -> NOT_FAMILY_OFFICE (BVF Inc is the general partner entity of BVF Partners L.P. (Biotechnology Value Fund), a San Francisco biotech investment manager with about $6.1bn of regulatory assets and a team of advisers, managing fund capital rather than one family's wealth.)
First seen by DFX
Sep 12, 2026
date not stated
BVF Inc/il: CANDIDATE_FAMILY_OFFICE -> PROBABLE_SFO (a 13F filer on no adviser roster that files nothing but ownership forms, with 1 private foundation(s) at its own address holding $220,336,715: the shape of a single family office (structural inference, no self-description found))
First seen by DFX
Sep 12, 2026
date not stated
BVF Inc/il files Form 13F (non_adviser_filer, $2,970,708,839 in 41 positions)
Occurred
May 15, 2026
BVF Inc/il reported $3,139,034,854 across 41 13(f) positions for the quarter ended 2026-03-31
Occurred
Mar 31, 2026
BVF Inc/il opened a $8,192,944 position in Onkure Therapeutics Inc (1,978,972 shares)
Occurred
Mar 31, 2026
BVF Inc/il exited Repare Therapeutics Inc (was $26,867,360, 10,333,600 shares)
Occurred
Mar 31, 2026
BVF Inc/il opened a $31,182,039 position in Sutro Biopharma Inc (1,251,788 shares)
Occurred
Mar 31, 2026
BVF Inc/il opened a $70,720,000 position in Alkermes Plc (2,000,000 shares)
Occurred
Mar 31, 2026
BVF Inc/il increased Imagenebio Inc 802,102 -> 1,110,002 shares ($5,534,504 -> $5,550,010)
Occurred
Mar 31, 2026
BVF Inc/il increased Nektar Therapeutics 1,559,595 -> 2,559,595 shares ($65,939,677 -> $184,162,860)
Occurred
Mar 31, 2026
BVF Inc/il reduced 4d Molecular Therapeutics in 4,629,289 -> 2,879,289 shares ($34,719,668 -> $26,806,181)
Occurred
Mar 31, 2026
BVF Inc/il exited Abivax Sa (was $68,510,521, 508,031 shares)
Occurred
Mar 31, 2026
BVF Inc/il opened a $16,650,000 position in Anteris Technologies Global (3,000,000 shares)
Occurred
Mar 31, 2026
BVF Inc/il exited Pepgen Inc (was $12,466,650, 1,915,000 shares)
Occurred
Mar 31, 2026
BVF Inc/il exited Axsome Therapeutics Inc (was $8,357,058, 45,757 shares)
Occurred
Mar 31, 2026
BVF Inc/il increased Disc Medicine Inc 650,000 -> 1,272,312 shares ($51,616,500 -> $81,351,629)
Occurred
Feb 17, 2026
BVF Inc/il reported $2,970,708,839 across 41 13(f) positions for the quarter ended 2025-12-31
Occurred
Dec 31, 2025
BVF Inc/il reduced Axsome Therapeutics Inc 486,757 -> 45,757 shares ($59,116,638 -> $8,357,058)
Occurred
Dec 31, 2025
BVF Inc/il reduced Septerna Inc 4,015,790 -> 1,720,782 shares ($75,537,010 -> $47,975,402)
Occurred
Dec 31, 2025
BVF Inc/il exited Cidara Therapeutics Inc (was $135,420,440, 1,414,165 shares)
Occurred
Dec 31, 2025
BVF Inc/il increased Stoke Therapeutics Inc 1,657,096 -> 2,265,674 shares ($38,941,756 -> $71,912,493)
Occurred
Dec 31, 2025
BVF Inc/il increased Crescent Biopharma Inc. 1,387,863 -> 2,748,763 shares ($16,501,691 -> $32,600,329)
Occurred
Dec 31, 2025
BVF Inc/il increased Compass Therapeutics Inc 4,750,000 -> 7,764,842 shares ($16,625,000 -> $41,697,202)
Occurred
Dec 31, 2025
BVF Inc/il increased Annexon Inc 7,000,000 -> 9,128,080 shares ($21,350,000 -> $45,822,962)
Occurred
Dec 31, 2025
BVF Inc/il exited Protagonist Therapeutics Inc (was $170,121,650, 2,560,916 shares)
Occurred
Dec 31, 2025
BVF Inc/il exited Celcuity Inc (was $32,525,997, 658,421 shares)
Occurred
Dec 31, 2025
BVF Inc/il exited Essa Pharma Inc (was $2,228,678, 11,668,473 shares)
Occurred
Dec 31, 2025
BVF Inc/il reduced Monte Rosa Therapeutics Inc 5,660,132 -> 3,835,886 shares ($41,941,578 -> $60,146,692)
Occurred
Dec 31, 2025
BVF Inc/il opened a $48,226,750 position in Invivyd Inc (19,525,000 shares)
Occurred
Dec 31, 2025
BVF Inc/il increased Xencor Inc 2,740,141 -> 7,133,720 shares ($32,141,854 -> $109,217,253)
Occurred
Dec 31, 2025
BVF Inc/il opened a $51,616,500 position in Disc Medicine Inc (650,000 shares)
Occurred
Dec 31, 2025
BVF Inc/il reduced Tyra Biosciences Inc 3,649,794 -> 2,127,665 shares ($51,060,618 -> $55,936,313)
Occurred
Nov 14, 2025
BVF Inc/il reported $2,466,911,543 across 46 13(f) positions for the quarter ended 2025-09-30
Occurred
Sep 30, 2025
BVF Inc/il opened a $6,537,131 position in Imagenebio Inc (802,102 shares)
Occurred
Sep 30, 2025
BVF Inc/il opened a $16,625,000 position in Compass Therapeutics Inc (4,750,000 shares)
Occurred
Sep 30, 2025
BVF Inc/il increased Cidara Therapeutics Inc 786,392 -> 1,414,165 shares ($38,305,154 -> $135,420,440)
Occurred
Sep 30, 2025
BVF Inc/il reduced Celcuity Inc 3,466,000 -> 658,421 shares ($46,271,100 -> $32,525,997)
Occurred
Sep 30, 2025
BVF Inc/il reduced Axsome Therapeutics Inc 1,690,221 -> 486,757 shares ($176,442,170 -> $59,116,638)
Occurred
Sep 30, 2025
BVF Inc/il increased Avalo Therapeutics Inc 1,028,049 -> 1,355,256 shares ($5,129,965 -> $17,225,304)
Occurred
Sep 30, 2025
BVF Inc/il opened a $47,376,832 position in Abivax Sa (558,031 shares)

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 office address (Form 13F) · as of 2026-05-15

Mark N. Lampert
President · Revealable: 1 business phone (Form 13F)

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Family Offices
Canonical id: dfx:fo:047506d3-9b4e-4640-8a43-9523b53109c7
First observed: n/a
Last observed: n/a : not yet measured
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

BVF Inc/il

Office on the family office graph

This is the graph view. The full profile, with its team, deals and sources, is on Family Offices.Open the full profile →

Search this name across graphsid dfx:fo:047506d3-9b4e-4640-8a43-9523b53109c7

Data as of an unrecorded date (this record's last observation) from Sworn filings; Announcements. Page built Sep 18, 2026, 10:56 PM UTC and rebuilt at most every 15 minutes.

Person

Title

Role

Seniority

Family member

Current

Evidence

Mark N. Lampert

President

leadership

senior

n/a

yes

fact